CDR-Life has inked a second licensing pact with Boehringer Ingelheim, as the Zurich-based startup will work with the German drug company in a ripe area of dealmaking. For 38 million Swiss francs (about $48 million) …
Blackstone to pay Merck $700M to fund development of antibody-drug conjugate
Blackstone Life Sciences will give a major financial boost to Merck’s development of an antibody-drug conjugate targeting TROP2, taking over some of the financial risk for an asset the drugmaker acquired through a 2022 partnership …
Pfizer reports revenue decline, boosts earnings guidance and trims pipeline
Even as Pfizer is embroiled in what has become pharma’s most dramatic M&A battle in years, it still has a business to run that has nothing to do with Metsera. The New …
South Korean biotech sets up California startup to advance ADCs
ABL Bio, a multi-partnered South Korean biotech, is backing a new Palo Alto, CA-based startup to carry forward two antibody-drug conjugates. NEOK Bio emerged on Tuesday with a $75 million Series A, with ABL Bio …
Post-Hoc Live: M&A, FDA, MFN and more — with our cousins at the FT
It’s been a heck of a week (and it’s only Tuesday). Today on Post-Hoc Live at 11 a.m. ET, I’ll be joined by my colleague at the Financial Times, Global Pharmaceutical Editor Hannah Kuchler. Next week, we’ll both be in London for the FT and Endpoints News Global Pharma and Biotech Summit, and we wanted […]
Lilly signs on as 2026 Milan Olympics sponsor, re-ups donations for each Team USA win
Eli Lilly is going for gold at the Milano Cortina 2026 Olympic and Paralympic Winter Games.
UCB bags FDA okay for first drug to treat rare disease TK2d
People living with thymidine kinase 2 deficiency (TK2d), a vanishingly rare and often fatal genetic disorder, finally have an approved therapy.
Compass plots quicker path to approval, launch readiness for depression drug
Compass Pathways said it is accelerating commercial plans for its psilocybin-based depression candidate after a discussion with the FDA about the potential for expedited approval. The drugmaker is pulling forward expected launch timelines for COMP360 …
Nuvation Bio backs off from head-to-head brain cancer trial
Post Content
Lilly reveals $3bn orforglipron facility in Netherlands
After so many announcements of new facility builds in the US, Eli Lilly has made a welcome commitment to a European investment.